Zacks Investment Research upgraded shares of Xeris Pharmaceuticals (NASDAQ:XERS) from a hold rating to a buy rating in a report released on Saturday, Zacks.com reports. The firm currently has $6.00 target price on the stock.
According to Zacks, “Xeris Pharmaceuticals, Inc. produces peptides, proteins, antibodies, molecules, auto-injectors, multi-dose pens and infusion pumps to treat endocrine and metabolic diseases. The company’s proprietary formulation technologies consist of XeriSol (TM) and XeriJect(TM). Xeris Pharmaceuticals, Inc. is based in Chicago, United States. “
A number of other research analysts have also recently commented on the company. Mizuho restated a buy rating and set a $14.00 price target on shares of Xeris Pharmaceuticals in a research note on Tuesday, May 26th. ValuEngine upgraded Xeris Pharmaceuticals from a buy rating to a strong-buy rating in a research note on Saturday, May 30th. Two investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $11.40.
XERS opened at $2.66 on Friday. Xeris Pharmaceuticals has a one year low of $1.42 and a one year high of $12.94. The stock has a market capitalization of $94.35 million, a PE ratio of -0.58 and a beta of 2.10. The business’s 50 day moving average price is $4.59 and its 200 day moving average price is $4.36. The company has a debt-to-equity ratio of 2.16, a quick ratio of 4.72 and a current ratio of 4.82.
Xeris Pharmaceuticals (NASDAQ:XERS) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.89) EPS for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.03. Xeris Pharmaceuticals had a negative return on equity of 323.82% and a negative net margin of 3,100.00%. The firm had revenue of $1.68 million for the quarter, compared to analysts’ expectations of $1.82 million. As a group, equities research analysts forecast that Xeris Pharmaceuticals will post -3.06 earnings per share for the current fiscal year.
In related news, insider Paul R. Edick acquired 33,000 shares of the business’s stock in a transaction dated Friday, May 8th. The shares were acquired at an average price of $3.54 per share, with a total value of $116,820.00. Following the completion of the transaction, the insider now owns 95,493 shares of the company’s stock, valued at $338,045.22. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider John Patrick Shannon, Jr. acquired 22,000 shares of the business’s stock in a transaction dated Wednesday, May 13th. The shares were bought at an average cost of $3.55 per share, for a total transaction of $78,100.00. Following the transaction, the insider now directly owns 117,493 shares of the company’s stock, valued at approximately $417,100.15. The disclosure for this purchase can be found here. 5.95% of the stock is currently owned by corporate insiders.
Several institutional investors have recently bought and sold shares of XERS. SG Americas Securities LLC purchased a new stake in shares of Xeris Pharmaceuticals during the first quarter worth $26,000. Deutsche Bank AG increased its position in shares of Xeris Pharmaceuticals by 40.7% during the first quarter. Deutsche Bank AG now owns 13,617 shares of the company’s stock worth $27,000 after acquiring an additional 3,942 shares during the period. Squarepoint Ops LLC purchased a new stake in shares of Xeris Pharmaceuticals during the first quarter worth $33,000. American International Group Inc. increased its position in shares of Xeris Pharmaceuticals by 26.3% during the first quarter. American International Group Inc. now owns 21,090 shares of the company’s stock worth $41,000 after acquiring an additional 4,394 shares during the period. Finally, M&T Bank Corp increased its holdings in Xeris Pharmaceuticals by 26.7% in the first quarter. M&T Bank Corp now owns 26,036 shares of the company’s stock valued at $51,000 after buying an additional 5,493 shares during the last quarter. 62.48% of the stock is currently owned by institutional investors and hedge funds.
About Xeris Pharmaceuticals
Xeris Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps.
See Also: What are retained earnings?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xeris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.